TriSalus Life Sciences (TLSI) Projected to Post Quarterly Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI) is projected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.

TriSalus Life Sciences Stock Performance

NASDAQ:TLSI opened at $5.65 on Wednesday. The company has a 50-day moving average of $5.36 and a 200-day moving average of $4.72. TriSalus Life Sciences has a 52 week low of $3.50 and a 52 week high of $10.42. The company has a market capitalization of $172.29 million, a price-to-earnings ratio of -2.27 and a beta of 0.48.

Insider Buying and Selling

In related news, CFO James Emmett Young purchased 24,000 shares of the stock in a transaction dated Monday, January 27th. The stock was bought at an average cost of $5.40 per share, for a total transaction of $129,600.00. Following the completion of the acquisition, the chief financial officer now owns 24,000 shares of the company’s stock, valued at approximately $129,600. This represents a ? increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sean Murphy bought 15,000 shares of the stock in a transaction on Monday, January 27th. The stock was purchased at an average cost of $5.31 per share, with a total value of $79,650.00. Following the acquisition, the insider now owns 182,732 shares in the company, valued at approximately $970,306.92. This represents a 8.94 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 54,856 shares of company stock worth $294,608. Corporate insiders own 32.80% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on TLSI. Roth Mkm reaffirmed a “buy” rating and issued a $11.00 price target on shares of TriSalus Life Sciences in a report on Friday, January 24th. Lake Street Capital started coverage on TriSalus Life Sciences in a report on Thursday, February 13th. They issued a “buy” rating and a $10.00 price target on the stock. Finally, Cantor Fitzgerald assumed coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $11.56.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.